CYYNF
Price
$0.08
Change
-$0.07 (-46.67%)
Updated
Jun 12 closing price
Capitalization
25.05M
DMAC
Price
$3.84
Change
+$0.03 (+0.79%)
Updated
Jun 27 closing price
Capitalization
164.68M
38 days until earnings call
Interact to see
Advertisement

CYYNF vs DMAC

Header iconCYYNF vs DMAC Comparison
Open Charts CYYNF vs DMACBanner chart's image
Cynata Therapeutics
Price$0.08
Change-$0.07 (-46.67%)
Volume$20K
Capitalization25.05M
DiaMedica Therapeutics
Price$3.84
Change+$0.03 (+0.79%)
Volume$3.19M
Capitalization164.68M
CYYNF vs DMAC Comparison Chart in %
Loading...
CYYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYYNF vs. DMAC commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYYNF is a Hold and DMAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CYYNF: $0.08 vs. DMAC: $3.84)
Brand notoriety: CYYNF and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYYNF: 322% vs. DMAC: 1740%
Market capitalization -- CYYNF: $25.05M vs. DMAC: $164.68M
CYYNF [@Biotechnology] is valued at $25.05M. DMAC’s [@Biotechnology] market capitalization is $164.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYYNF’s FA Score shows that 1 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • CYYNF’s FA Score: 1 green, 4 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, CYYNF is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYYNF’s TA Score shows that 3 TA indicator(s) are bullish while DMAC’s TA Score has 6 bullish TA indicator(s).

  • CYYNF’s TA Score: 3 bullish, 3 bearish.
  • DMAC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than CYYNF.

Price Growth

CYYNF (@Biotechnology) experienced а 0.00% price change this week, while DMAC (@Biotechnology) price change was +6.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

DMAC is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMAC($165M) has a higher market cap than CYYNF($25.1M). DMAC YTD gains are higher at: -29.282 vs. CYYNF (-57.895). CYYNF has higher annual earnings (EBITDA): -10.8M vs. DMAC (-29.04M).
CYYNFDMACCYYNF / DMAC
Capitalization25.1M165M15%
EBITDA-10.8M-29.04M37%
Gain YTD-57.895-29.282198%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A36.3M-
Total DebtN/A316K-
FUNDAMENTALS RATINGS
CYYNF vs DMAC: Fundamental Ratings
CYYNF
DMAC
OUTLOOK RATING
1..100
5047
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9661
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
55n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYYNF's Valuation (32) in the null industry is in the same range as DMAC (61) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to DMAC’s over the last 12 months.

CYYNF's Profit vs Risk Rating (100) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to DMAC’s over the last 12 months.

CYYNF's SMR Rating (98) in the null industry is in the same range as DMAC (98) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for CYYNF (96) in the null industry. This means that DMAC’s stock grew somewhat faster than CYYNF’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CYYNF (100) in the null industry. This means that DMAC’s stock grew similarly to CYYNF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYYNFDMAC
RSI
ODDS (%)
Bullish Trend 3 days ago
38%
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
N/A
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
38%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
46%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
19%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
30%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
N/A
Bearish Trend 14 days ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
54%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CYYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZNOG0.19N/A
+2.43%
Zion Oil & Gas, Inc.
PGPEF109.25N/A
N/A
Publicis Groupe S.A.
RWWI14.60N/A
N/A
Rand Worldwide, Inc.
SSSAF43.93N/A
N/A
SHURGARD SELF STORAGE LTD.
NRGYF0.07N/A
N/A
New Energy Metals Corp.

CYYNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYYNF has been loosely correlated with HLOSF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CYYNF jumps, then HLOSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYYNF
1D Price
Change %
CYYNF100%
N/A
HLOSF - CYYNF
39%
Loosely correlated
N/A
DMAC - CYYNF
30%
Poorly correlated
+0.79%
PALI - CYYNF
21%
Poorly correlated
-1.93%
CVALF - CYYNF
6%
Poorly correlated
N/A
FAMDF - CYYNF
2%
Poorly correlated
N/A
More

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+0.79%
WHWK - DMAC
42%
Loosely correlated
+1.58%
HUMA - DMAC
34%
Loosely correlated
-4.50%
VICP - DMAC
33%
Poorly correlated
N/A
ELDN - DMAC
31%
Poorly correlated
-1.82%
CYYNF - DMAC
30%
Poorly correlated
N/A
More